BofA Upgrades Pharvaris: What Investors Need to Know
BofA upgrades Pharvaris to Neutral ($27 target). Unique oral drug for angioedema treatment, but current price assumes success of upcoming data.
/ 935 items
#Healthcare↓
TransCode Therapeutics Acquires Polynoma and Secures $25M Funding to Advance Cancer Treatments
TransCode Therapeutics acquires Polynoma LLC and receives $25M investment from CK Life Sciences to develop innovative cancer therapies, including melanoma vaccine and microRNA treatments.
JPMorgan Boosts Ionis Stock Rating on Strong Drug Pipeline
JPMorgan analyst upgrades Ionis Pharmaceuticals to Overweight, raising price target to $80 from $49, citing strong drug launches and path to profitability.
Promising New Treatment Shows Hope for Lewy Body Dementia Patients
CervoMed announces positive Phase 2b trial results for neflamapimod in treating dementia with Lewy bodies, showing significant improvements in cognitive decline and neurodegeneration markers.
Zenas BioPharma Secures $2B+ Deal for MS Drug from InnoCare
Zenas BioPharma acquires global rights to orelabrutinib, an experimental multiple sclerosis drug from InnoCare Pharma, in a licensing deal worth over $2 billion with $120M funding secured.
Lexeo's Friedreich Ataxia Treatment Accelerates FDA Review
Lexeo Therapeutics' gene therapy, LX2006, is moving faster toward FDA approval for Friedreich's ataxia cardiomyopathy.